Table 1.
Baseline characteristics of 228 patients treated on their pelvis with curative intent
| Age, median (IQR) | 65 (57–71) |
| Treatment period, n (%) | |
| 1969–1987 | 9 (3.9) |
| 1988–1993 | 13 (5.7) |
| 1994–2000 | 30 (13) |
| 2001–2012 | 139 (61) |
| 2013–2016 | 37 (16) |
| Pelvic treatment as part of first treatment, n (%) | 154 (68) |
| Pathological T stage, n (%) | |
| pT1 | 29 (13) |
| pT2 | 100 (44) |
| pT3 | 75 (33) |
| pT4 | 10 (4.4) |
| pTx | 14 (6.1) |
| Differentiation, n (%) | |
| Grade 1 | 34 (15) |
| Grade 2 | 102 (45) |
| Grade 3 | 77 (34) |
| Unknown | 15 (6.6) |
| Positive primary tumour resection margin, n (%) | 24 (11) |
| Clinical N stage, n (%) | |
| cN0 | 31 (14) |
| cN1 | 86 (38) |
| cN2 | 40 (18) |
| cN3 | 71 (31) |
| Suspicious pelvic nodes on imaging, n (%) | |
| None | 47 (21) |
| Unilateral | 45 (20) |
| Bilateral | 20 (8.8) |
| ≥2 tumour-positive inguinal lymph nodes per groin at pathology, n (%) | |
| Unilateral | 94 (41) |
| Bilateral | 44 (19) |
| Inguinal ENE at pathology, n (%) | |
| Unilateral | 85 (37) |
| Bilateral | 34 (15) |
IQR = interquartile range; ENE = extranodal extension.